
Aurora hospitals among the best in the U.S. for patient safety
Nine Aurora Health Care hospitals have received an 'A' rating from The Leapfrog Group for excellence in patient safety, once again giving Aurora Health Care the most A's for any health system in Wisconsin.
Leapfrog analysts use publicly available data to look at 22 different safety measures and assign grades based on how well hospitals are doing to protect patients from harm. Measurements include the hospital's ability to prevent errors, accidents, injuries and infections. Leapfrog Hospital Safety Grades are assigned to nearly 3,000 general acute-care hospitals across the nation twice a year.
Aurora Health Care hospitals that received 'A' ratings include:
Aurora BayCare Medical Center
Aurora Medical Center — Burlington
Aurora Medical Center — Grafton
Aurora Lakeland Medical Center
Aurora Medical Center Manitowoc County
Aurora Medical Center Sheboygan County
Aurora Medical Center — Summit
Aurora Medical Center Washington County
Aurora West Allis Medical Center
'We are truly honored to receive more 'A' ratings from The Leapfrog Group than any other health system in Wisconsin, as this recognition reflects our team's dedication to serving our community with compassionate, innovative and high-quality clinical care,' said Gabrielle Finley-Hazle, president, Aurora Health Care. 'Our dedicated teammates across the state work hard to provide the best care for our patients every day, and this achievement demonstrates our commitment to delivering safe, effective care and enhancing patient outcomes for everyone in the communities we have the privilege to serve.'
Aurora's commitment to patient safety
Aurora Health Care takes a multidisciplinary approach to standardizing care and the key quality reporting metrics that drive patient safety and better patient outcomes. Quality reporting metrics are standardized measures that track various aspects of patient care, such as treatment outcomes, infection rates and patient satisfaction. These are among the 22 safety measures graded by Leapfrog, along with hand hygiene, nurse and doctor communications and hospital-acquired conditions.
As a health system, Aurora sets top priorities on patient experience, infection prevention and patient safety indicators like bed sores, fall prevention and complications from surgery. By aligning and gathering data along these key indicators, Aurora is able to get real-time performance feedback and respond quickly to address potential risks and areas of improvement.
This process also helps foster a culture of continuous improvement. By regularly monitoring performance, Aurora is able to set statewide benchmarks and goals, identify and share best practices across its sites in Wisconsin, and drive improvements in patient safety.
'We recognize that patients have many choices on where to receive care, and they rely on awards, recognitions and public data to make these important decisions,' said Melissa Spiering, vice president of quality and regulatory for Aurora Health Care. 'These designations from Leapfrog further uphold our longstanding commitment to quality and safety and help ensure our communities know we are focused on improving patient outcomes and achieving clinical preeminence.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 days ago
- Yahoo
Aurora Expands Medical Cannabis Offerings in Australia with the Launch of IndiMed TEMPO 22
NASDAQ | TSX: ACB Canada's Largest Medical Cannabis Company Adds Two New Cultivars to Popular Brand Portfolio in the Australian Market EDMONTON, AB, June 5, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, has expanded their popular IndiMed brand with the launch of IndiMed TEMPO 22, available through the company's subsidiary, MedReleaf Australia. With the same consistent quality and reliable supply, this new 22% THC potency creates a greater range of treatment options available to prescribers. "Expanding our portfolio in the value segment in Australia reinforces our commitment to meet increasingly diversified patient needs with accessible, high-quality medical cannabis options," said Andre Jerome, Executive Vice President of Global Business Development at Aurora. "As a global leader in medical cannabis, we're proud to offer a diverse range of products that reflect both local demand and our dedication to innovation worldwide." IndiMed remains one of the most prescribed medical cannabis brands for patients in Australia. The two new cultivars available include: IndiMed TEMPO 22 | Lemon Laser – Sativa, 22% THC, <1% CBD, Dried Cannabis (15g) IndiMed TEMPO 22 | Pickled Petrol – Indica, 22% THC, <1% CBD, Dried Cannabis (15g) Aurora's continued focus on international growth and deep commitment to providing patients with innovative products and expanded access enables the company to maintain its global leadership position. MedReleaf Australia, a wholly owned subsidiary of Aurora, is committed to quality and proudly meeting all TGA-GMP standards. For further information about the company's offerings, doctors and health care professionals can contact MedReleaf Australia's clinical support team or visit their website: About Aurora Cannabis Inc. Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at and follow us on X and LinkedIn. Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB". Contact For Media: Michelle Lefler | VP, Communications & PR | media@ For Investors: ICR, Inc. | aurora@ Forward Looking Information This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding: the expansion of the Company's medical cannabis offerings in Australia and the availability of specific products; the Company's commitment to innovation, quality and expanded access; the Company's continued focus on international growth; and the Company's global leadership position. These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 20, 2024 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at and filed with and available on the SEC's website at The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. View original content to download multimedia: SOURCE Aurora Cannabis Inc. Sign in to access your portfolio
Yahoo
4 days ago
- Yahoo
Aurora Cannabis to Host Fourth Quarter and Fiscal Year 2025 Investor Conference Call and File Related Year End Information
NASDAQ | TSX: ACB EDMONTON, AB, June 3, 2025 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its fourth quarter and fiscal year 2025 on Wednesday, June 18, 2025 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the fourth quarter fiscal year 2025 before the opening of markets that same day. Conference Call Details DATE: Wednesday, June 18, 2025 TIME: 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time WEBCAST: Click Here Miguel Martin, Executive Chairman and Chief Executive Officer, and Simona King, Chief Financial Officer, will host the conference call and question and answer period. This weblink has also been posted to the Company's "Investor Info" link at under "Events". About Aurora Cannabis Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult- use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at and follow us on X and LinkedIn. Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB". Forward Looking Statements This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the timing of the release of the Company's financial statements for fourth quarter and fiscal year ended March 31, 2025 and scheduling of the conference call to discuss results. These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the timing, magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 20, 2024 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at and filed with and available on the SEC's website at The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. View original content to download multimedia: SOURCE Aurora Cannabis Inc. View original content to download multimedia: Sign in to access your portfolio

Yahoo
4 days ago
- Yahoo
Milwaukee man charged in wrong-way crash on I-43 that killed two and injured one
A Milwaukee man has been arrested and charged in connection with a wrong-way crash on Memorial Day on Interstate 43 in the Town of Port Washington area that killed two people and seriously injured another. Ace Vue, 34, was charged with two counts of first-degree reckless homicide in the deaths of Nicole Horne, 51, and Jay Horne, 56, of Oostburg. Vue was also charged with one count of first-degree reckless injury for seriously injuring 22-year-old passenger Alissa Horne. The charges could come with a fine of up to $100,000 and a prison term of up to 145 years. The crash happened at 12:44 a.m. May 26. According to the criminal complaint: Vue got on I-43 in the Town of Belgium, driving southbound in the northbound lanes. He was "swerving and excessively speeding." Other cars flashed their lights and honked as he passed by. At least five people called 911. When Vue hit the Horne's vehicle, dash camera footage from Vue's vehicle showed a vehicle speed of 92 mph. A deputy who investigated the crash said both vehicles sustained "substantially devastating damage." Nicole Horne and Jay Horne were pronounced dead at the scene. Alissa Horne was pinned in the backseat but was conscious. Deputies were able to extricate both Alissa Horne and Vue from their vehicles. Alissa Horne was taken by Port Washington Fire and Rescue to Froedtert Hospital in Wauwatosa. Vue was taken to Aurora Medical Center in Grafton and then was flown by Flight for Life to Froedtert. Vue was arrested at his home on June 2, according to an updated news release from the Ozaukee County Sheriff's Office. The Sheriff's Office said Vue was released from the hospital sometime over the weekend of May 31-June 1 without the sheriff's office being notified. On June 3, Vue will appear in court for an initial appearance. Contact Claudia Levens at clevens@ Follow her on X at @levensc13. This article originally appeared on Milwaukee Journal Sentinel: Milwaukee man arrested and charged in fatal wrong-way crash on I-43